Abdulrahman Al-Mashdali: Targeted Therapies for CNS Involvement in CLL
Abdulrahman Al-Mashdali, Hematology Chief Fellow at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Therapeutic Advances in Hematology, adding:
”I’m pleased to share our newly published systematic review in Therapeutic Advances in Hematology:
‘Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review.’
CNS involvement in CLL/SLL is rare, diagnostically challenging, and historically associated with poor outcomes. In this systematic review, we analyzed 26 studies including 32 patients treated with novel targeted therapies.
Key findings:
- 94.1 percent overall response rate across 34 treatment regimens
- 55.9 percent complete responses and 38.2 percent partial responses
- Ibrutinib was the most frequently used targeted agent
- Venetoclax and ibrutinib–venetoclax combinations demonstrated encouraging activity
- Responses were observed even in patients with adverse biological features such as TP53 abnormalities, del(17p), and unmutated IGHV
While these findings are encouraging, the evidence remains largely based on case reports and small series. Prospective multicenter studies are needed to better define treatment sequencing, combination strategies, and the role of intrathecal therapy and radiotherapy.
I’m grateful to all my co-authors and colleagues who contributed to this work.”
Title: Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review
Authors: Abdulrahman F. Al-Mashdali, Mujahid O. Abdelraof, Raga M. Mukhtar, Shehab F. Mohamed,

Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian